Anti-coagulants and risk for ED visits

In this large retrospective database analysis, researchers found the risk of hemorrhage-related ED visits were 1.2 per 1000 prescriptions for dual anti-platelet therapy, and 2.5 per 1000 prescriptions for warfarin. The risk of hemorrhage-related hospitalizations for these ED visits was no different between the groups (abstract). This better quantifies the risk of bleeding with these medication choices

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment